Introduction
============

Elevation of creatine kinase-MB (CK-MB) isoenzyme due to myonecrosis after elective percutaneous coronary intervention (PCI) can be detected in 5%--30% of patients ([@b2-vhrm-4-1417]; [@b7-vhrm-4-1417]; [@b24-vhrm-4-1417]; [@b26-vhrm-4-1417]; [@b3-vhrm-4-1417]). Factors related to the procedure such as side-branch occlusion, intimal dissection, and distal embolization have been suggested as possible causes of increased cardiac enzymes after PCI ([@b1-vhrm-4-1417]; [@b24-vhrm-4-1417]; [@b26-vhrm-4-1417]). Other possible mechanisms are coronary vasospasm and no reflow phenomenon ([@b8-vhrm-4-1417]). Several studies have reported that elevated cardiac markers such as CK-MB and cardiac troponins (cTn) after PCI is associated with an increase in cardiac mortality and morbidity during follow-up ([@b1-vhrm-4-1417]; [@b7-vhrm-4-1417]; [@b24-vhrm-4-1417]; [@b26-vhrm-4-1417]).

Previous studies suggested intracoronary administration of calcium channel blockers (CCBs) is effective for resolving coronary spasm and no-reflow phenomenon ([@b19-vhrm-4-1417]; [@b29-vhrm-4-1417]). To our knowledge there is no data about the effects of administration of oral CCBs on CK-MB levels after PCI.

The aim of this study was to investigate the effect of CCBs used perorally on CK-MB levels in patients undergoing elective PCI.

Methods
=======

Patient population and study protocol
-------------------------------------

The study was approved by the local Ethics Committee of Baskent University Hospital in Ankara, Turkey. All patients undergoing PCI between December 2000 and December 2005 at our institution were evaluated for eligibility for this study, and all provided written informed consent before participating. Patients who were taking a CCB at the discretion of their own primary physician on admission were noted and the drug at the same dose was continued during the hospitalization period and thereafter. No CCBs were prescribed to the patients who were not already on one. Patients presenting with acute or recent myocardial infarction (MI) within 7 days, renal insufficiency with creatinine levels higher than 1.4 mg/dL, and those in whom use of a special device (laser, rotational atherectomy, brachy-therapy, etc) was planned were excluded. A total of 570 patients with elective PCI history were included in the study (mean age 60.1 ± 9.8 years, 74.4% males). The patients who were on a CCB on admission constituted the CCB group while the others served as controls.

There were 217 patients (mean age 60.2 ± 9.3 years, 74.7% males) in the CCB group and 353 patients (mean age 60.0 ± 10.1 years, 74.2% males) in the control group. Ninety percent of the patients in the CCB group were receiving diltiazem 180 mg/day, whereas others were receiving amlodipine 10 mg/day, felodipine 4 mg/day, or verapamil 240 mg/day.

All interventions were performed via the femoral approach. The choices of technique (percutaneous transluminal coronary angioplasty \[PTCA\], PTCA + stent, stent only) and adjunctive pharmacologic management were at the discretion of the operator according to the lesion characteristics. Angiographic success was defined as a residual stenosis of the treated lesion \<50% on visual estimation and -in case of stenting- desired position of the stent with Thrombolysis in Myocardial Infarction grade III flow. Commercially available drug-eluting and bare metal stents were used. All patients received aspirin 300 mg/day, and 75-mg maintance dose of clopidogrel.

Laboratory analyses
-------------------

Creatine kinase-MB isoform was measured routinely before PCI and 6, 24, and 36 h after PCI. Additional measurements were done for clinical indications. Levels of CK-MB were determined by an immunoinhibition assay (Roche Diagnostics, GmbH, Mannheim, Germany). The reference limit for CK-MB with this method is 0--24 U/L. CK-MB levels were considered elevated if the measurement was above the normal limit in any of the follow-up measurements. The CK-MB levels were further subdivided into 1 to 3 times (24--72 U/l) and 3 to 5 times (73--120 U/l) of the normal levels.

Statistical analysis
--------------------

The statistical package, SPSS version 9.0 (SSPS Inc., Chicago, IL, USA) was used for statistical analyses. Continuous variables with normal distribution were compared using the unpaired Student's t-test and were presented as the mean ± SD. Continuous variables with abnormal distributions were compared using the Mann-Whitney U test, and CK-MB results for each group were expressed as median and interquartile ranges. The CK-MB elevation within the groups were compared with the general lineer model for repeated measures test. Categorical data were reported as frequencies and percentages. Comparisons between categorical variables were performed using Fisher exact tests if any subgroup consisted of five or fewer items; otherwise, chi-square tests were used. Values for *p* less than 0.05 were considered statistically significant.

Results
=======

Baseline clinical and laboratory characteristics were similar between two groups ([Table 1](#t1-vhrm-4-1417){ref-type="table"}). The angiographic and procedural characteristics of the patients are listed in [Table 2](#t2-vhrm-4-1417){ref-type="table"}. No differences were observed between the groups (all p \> 0.05). No patients died during the study period. Major adverse effects which included coronary artery spasm or dissection, the need for blood transfusion and subacute occlusion were not different between the groups ([Table 2](#t2-vhrm-4-1417){ref-type="table"}).

Baseline CK-MB levels were similar in patients in the CBB and control groups ([Table 3](#t3-vhrm-4-1417){ref-type="table"}). During in-hospital follow-up period for 36 hours, CK-MB levels increased above the normal values in 41 patients (18.9%) of the CCBs group and in 97 patients (27.5%) of the control group (p = 0.02). The incidence of CK-MB elevation 1 to 3 times normal was 18.9% vs 26.9% (p = 0.03); 3 to 5 times normal was 0.5% vs 3.1% (p = 0.03) in the CCB and control groups, respectively. Three patients (0.8%) in the control group and none in the CCB group had CK-MB levels 5 times normal (p = 0.29). The diagnosis of postprocedural MI was based on either an increase in CK-MB 3 times the upper limit of normal, or development of pathologic Q waves in 2 or more contiguous electrocardiographic leads.

The median CK-MB levels were significantly higher in the control group compared with CCBs group at 6 h, 24 h, 36 h after PCI ([Table 3](#t3-vhrm-4-1417){ref-type="table"}). The elevations of CK-MB levels were statistically significant within the groups (both p \< 0.001) ([Figure 1](#f1-vhrm-4-1417){ref-type="fig"}).

Discussion
==========

Both previous retrospective studies and prospective randomized trials have shown that development of new treatment strategies like intracoronary nitrate infusion, oral statins, glycoprotein IIb/IIIa inhibitors and adenosine reduce ischemic complications, death, nonfatal myocardial infarction, and release of CK-MB after coronary interventions when compared with placebo ([@b13-vhrm-4-1417]; [@b17-vhrm-4-1417]; [@b10-vhrm-4-1417]; [@b15-vhrm-4-1417]; [@b5-vhrm-4-1417], [@b4-vhrm-4-1417]; [@b28-vhrm-4-1417]; [@b20-vhrm-4-1417]). Moreover, recently published trials demonstrated beneficial effects of beta blockers on CK-MB levels in patients with PCI as well ([@b21-vhrm-4-1417]; [@b23-vhrm-4-1417]; [@b11-vhrm-4-1417]; [@b28-vhrm-4-1417]; [@b22-vhrm-4-1417]).

Several studies have shown that intracoronary administration of CCBs reduces procedural myonecrosis in patients undergoing elective or urgent PCI. [@b8-vhrm-4-1417] and [@b29-vhrm-4-1417] have reported that intracoronary verapamil has favourable effects on coronary vasospasm and no-reflow phenomenon in patients with primary PTCA for acute MI. In VAPOR (VAsodilator Prevention On no-Reflow) trial intragraft verapamil was given pre-PCI to prevent no-reflow and there was a trend toward improved myocardial perfusion as assessed using the TIMI myocardial perfusion grade (TMPG) ([@b19-vhrm-4-1417]). In the VESPA (VErapamil Slow-Release for Prevention of Cardiovascular Events After Angioplasty) trial, 240 mg/d verapamil administered for six months after PCI reduced the incidence of need for repeat target vessel revascularization ([@b6-vhrm-4-1417]). A new recent meta-analysis of the two largest trials, Nisoldipine in Coronary artery Disease in Leuven (NICOLE) and Coronary Angioplasty Amlodipine in Restenosis Study (CAPARES), found that CCBs improved long term clinical outcome and reduced the need for target vessel revascularization when compared with placebo ([@b9-vhrm-4-1417]). It was concluded that this might be due to the antiproliferative properties of CCBs which were demonstrated in *in vitro* experiments ([@b30-vhrm-4-1417]; [@b27-vhrm-4-1417]). Moreover, the recently published trial by [@b18-vhrm-4-1417] demonstrated that using intracoronary CCB at the time of PCI result in lower postprocedural creatine phosphokinase (CPK) values and smaller areas under the CPK curve.

The aim of our study was to evaluate the relationship between systemic administration of CCBs and the elevation of CK-MB suggestive of myonecrosis. The results indicate that in elective PCI, per procedural CCBs usage may be associated with reduced CK-MB release. The cardioprotective effects of CCBs' observed in our study can be explained by several mechanisms.

[@b16-vhrm-4-1417] have found that the development of infarcts were significantly delayed and the mean infarct sizes were smaller with intracoronary infusion of diltiazem, verapamil or nifedipine indicating that CCBs increase the ischemic tolerance significantly by their effects on calcium homeostasis in the setting of acute ischemia during baloon inflations at PCI.

The CCBs may also protect the patients against fatal or nonfatal infarction via their platelet-inhibiting effects. [@b14-vhrm-4-1417] have reported that IV amlodipine administration was found to be protective against exacarbation of coronary thrombosis by epinephrine in dog model of experimental coronary artery thrombosis.

CCBs' may also improve nitric oxide (NO) release and improve endothelial functions ([@b25-vhrm-4-1417]). The ENCORE Investigators (Evaluation of Nifedipine and Cerivastatin on Recovery of Coronary Endothelial function) have reported that 30 to 60 mg/d nifedipine treatment over a 6 month period improved coronary endothelial function in the most constricted segment. Mechanisms that could be targeted by CCBs' include antioxidative properties and effects on endothelial nitric oxide synthase (eNOS) expression and activity ([@b12-vhrm-4-1417]). The present study was not designed to evaluate the mechanism by which CCBs might prevent myonecrosis after PCI and we do not know the factors affecting our results.

Study limitations
-----------------

There are several limitations of this study. This study is a nonrandomized study with lack of clinical follow-up. The patient numbers in the present study are small and lack the ability of a prospective randomized trial to minimize differences between the groups. The groups were formed before the study and the patients who were receiving CCBs at the discretion of their physician constituted the drug group, so the patients used different types and doses of CCBs. We did not collect any data on myocardial perfusion by angiography (TIMI frame count, myocardial perfusion blush scores), dynamic ST-segment changes to identify a relation with no-reflow at any time during mechanical perfusion. The number of patients with CK-MB elevations in both groups was small, and all patients at both groups had a very low incidence of MI after PCI.

Conclusion
==========

Despite these limitations, the study points out that systemic administration of CCBs may be associated with reduced CK-MB release after elective PCIs. Long-term prospective randomized trials are required to confirm the effects of CCBs on myocyte necrosis in patients undergoing elective PCI.

**Disclosure**

None of the authors have associations that might pose a conflict of interest. No financial support from any organization was used.

![Mean CK-MB levels of the groups during follow-up.\
**Abbreviations:** CCB, calcium channel blockers; CK-MB, creatine kinase-MB.](vhrm-4-1417f1){#f1-vhrm-4-1417}

###### 

Baseline clinical and laboratory features of CCB and control groups

                                         CCB group n = 217      Control group n = 353   *P* value
  -------------------------------------- ---------------------- ----------------------- -----------
  *Clinical characteristics*                                                            
    Age (year)                           60.2 ± 9.3             60.0 ± 10.1             0.79
    Sex, male, n (%)                     162 (74.7)             262 (74.2)              0.90
    SAP/USAP, n (%)                      140 (64.5)/77 (35.5)   232 (65.7)/121 (34.3)   0.77
    Diabetes mellitus, n (%)             50 (23.0)              102 (28.9)              0.14
    Hypertension, n (%)                  137 (63.1)             193 (54.7)              0.05
    Dyslipidemia, n (%)                  135 (62.2)             217 (61.5)              0.67
    Smoking, n (%)                       92 (42.4)              142 (40.2)              0.78
    History of PCI, n (%)                49 (22.6)              53 (15.0)               0.05
    History of CABG, n (%)               43 (19.8)              58 (16.4)               0.33
    Mean LVEF, %                         47 ± 11                48 ± 12                 0.69
  *Drugs*                                                                               
    ACE inhibitors, n (%)                73 (33.6)              149 (42.2)              0.05
    Statins, n (%)                       134 (61.8)             228 (64.6)              0.49
    Nitrates, n (%)                      66 (30.4)              131 (37.1)              0.11
  *Laboratory Findings*                                                                 
    Fasting blood sugar levels (mg/dL)   111.9 ± 42.2           115.3 ± 45.6            0.45
    Blood urea nitrogen levels (mg/dL)   17.9 ± 5.9             18.3 ± 6.5              0.65
    Creatinine (mg/dL)                   1.1 ± 0.8              1.1 ± 0.6               0.99
    LDL cholesterol (mg/dL)              112.3 ± 39.3           111.3 ± 38.6            0.79
    Triglyceride (mg/dL)                 154.5 ± 76.6           164.5 ± 94.5            0.28
    Hemoglobin (g/dL)                    14.1 ± 1.6             13.7 ± 1.7              0.06

**Abbreviations:** CCB, calcium channel blocker; PCI, percutaneous coronary interventions; CABG, coronary artery bypass graft surgery; LVEF, left ventricular ejection fraction; SAP, stable angina pectoris; USAP, unstable angina pectoris; ACE, angiotensin-converting enzyme; LDL, low-density lipoprotein.

###### 

Details of PCI procedures between groups

                                      CCB group n = 217   Control group n = 353   *P* value
  ----------------------------------- ------------------- ----------------------- -----------
  Dilated coronary artery                                                         
    Left anterior descending, n (%)   89 (41.0)           174 (49.3)              0.05
    Left circumflex, n (%)            79 (36.4)           118 (33.4)              0.46
    Right coronary artery, n (%)      74 (34.1)           100 (28.3)              0.15
    Graft lesion, n (%)               13.0 (6.0)          13 (3.7)                0.19
    Multi-vessel PCI, n (%)           41 (18.9)           60 (17.0)               0.56
  Drug-eluting stent, n (%)           5 (2.3)             11 (3.1)                0.79
  Stent used per procedure, n (%)     1.3 ± 0.4           1.3 ± 0.4               0.77
  Mean stent length (mm)              13.3 ± 6.5          13.3 ± 6.7              0.92
  Mean stent diameter (mm)            2.9 ± 0.4           3.0 ± 0.4               0.16
  Total inflation time, s             124.2 ± 85.7        114.8 ± 83.3            0.23
  Max inflation pressure, atm         11.8 ± 5.4          11.8 ± 4.1              0.99
  Spasm, n (%)                        6 (2.8)             6 (1.7)                 0.39
  Dissections, n (%)                  3 (1.4)             6 (1.7)                 1.00
  Blood transfusion, n (%)            2 (0.9)             3 (0.8)                 1.00
  Subacute occlusion, n (%)           5 (2.3)             7 (2.9)                 0.77

**Abbreviations:** CCB, calcium channel blockers; CK-MB, creatine kinase-MB; PCI, percutaneous coronary interventions.

###### 

Median (interquartile range) CK-MB levels of the groups during follow-up

                                     CCB group n = 217   Control group n = 353   *P* value
  ---------------------------------- ------------------- ----------------------- -----------
  Baseline CK-MB, U/L                11.0 (7.0--16.0)    12.0 (8.0--17.0)        0.13
  After PCI, 6th hours CK-MB, U/L    14.0 (8.2--21.0)    15 (10.2--21.0)         0.03
  After PCI, 24th hours CK-MB, U/L   13.0 (9.0--19.7)    16.0 (11.0--22.0)       0.001
  After PCI, 36th hours CK-MB, U/L   13.0 (8.0--20.0)    15.0 (10.0--24.0)       0.000

**Abbreviations:** CCB, calcium channel blockers; CK-MB, creatine kinase-MB; PCI, percutaneous coronary interventions.
